2003 - Present
Jewell MA, Golden W, Keck P et al. The STAndards for BipoLar Excellence (STABLE) Project: A bipolar disease quality improvement initiative to develop and validate evidence-based performance measures for national endorsement. Poster presented at 13th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, May 5, 2008.

Golden WE, Keck PE, Jr., Sachs GS, Oldham JM, Brewster C, Ross R. The STABLE Project: Addressing the Gap Between Evidence and Practice for Bipolar Disorder. J Psychiatr Pract 2008;14(suppl 2) in press.

Brewster C. Overview of the STAndards for BipoLar Excellence (STABLE) Project. J Psychiatr Pract 2008;14(suppl 2):5-7.

Oldham JM, Golden WE, Rosof BM. Quality Improvement in Psychiatry: Why Measures Matter. J Psychiatr Pract 2008;14(suppl 2):8-17.

Golden WE, Hermann RC, Jewell M, Brewster C. Development of Evidence-Based Performance Measures for Bipolar Disorder: Overview of Methodology. J Psychiatr Pract 2008;14(suppl 2):18-30.

Keck PE, Jr. Kessler RC, Ross R. Clinical and Economic Effects of Unrecognized or Inadequately Treated Bipolar Disorder. J Psychiatr Pract 2008;14(suppl 2):31-38.

Sachs GS. Psychosocial Interventions as Adjunctive Therapy for Bipolar Disorder. J Psychiatr Pract 2008;14(suppl 2):39-44.

Stotland NL, Mattson MG, Bergeson S. The Recovery Concept: Clinician and Consumer Perspectives. J Psychiatr Pract 2008;14(suppl 2):45-54.

Williams JW, Jr., Manning JS. Collaborative Mental Health and Primary Care for Bipolar Disorder. J Psychiatr Pract 2008;14(suppl 2):55-64.

Miller BS, Shulman D, Shillington AC, et al. Consensus and discordance in treating recombinant human growth hormone (rhGH) treated patients: results of a knowledge (K), attitudes (A), beliefs (B) and practices (P) [KABP] survey. Pediatric Academic Societies’ & Asian Society for Pediatric Research Joint Meeting, Honolulu, Hawaii, May 2-6, 2008.

Harshaw Q, Wygant GD, Hauch O, Berger JS, Frye CB, Becker RC. Pharmacoeconomic analysis of bleeding complications and reoperation costs in patients with ACS receiving clopidogrel who require CABG surgery. AHA 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Baltimore, Maryland, May 1-2, 2008.

Pickard AS, Becker RC, Schumock GT, Frye CB. Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. Pharmacotherapy. 2008;28(3):376-392.

Patel B, Sheridan P, Detjen P, et al. Success of a Comprehensive school-based asthma intervention on clinical markers and resource utilization for inner-city children with asthma in Chicago: the Mobile C.A.R.E. Foundation's asthma management program. Journal of Asthma. 2007;44(2):113-118.

Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC. Impact of thienopyridines on bleeding complications with ACS patients requiring CABG surgery. Scientific Sessions, 2007, American Heart Association (AHA), Orlando, Florida, November 4-7, 2007. (Abstract #8663, Presentation #3221). Midwest AHA Affiliate, Chicago, Illinois, November 19, 2007. American College of Clinical Pharmacy, Phoenix, Arizona, April 7, 2008.

Gathe Jr. JC, Yeh RF, Mayberry C, et al. Single-agent Therapy with Lopinavir/ritonavir Suppresses Plasma HIV-1 Viral Replication in HIV-1 Naïve Subjects: IMANI-2 48-Week Results. 4th IAS Conference,Sydney, Australia. 22-25 July 2007. Poster # WEPEB034.

Lustig R, Meacham L, Frane J, Frye C, Bakker B. Linear growth and BMI during growth hormone treatment of children with craniopharyngioma compared to other organic growth hormone deficiencies: the National Cooperative Growth Study experience. 46th Annual Meeting of the European Society for Paediatric Endocrinology, Helsinki, Finland, June 27-30, 2007. (Poster # PO2-489).

Rawlings MK, McGhee TA, Casey-Bailey S, Pasley M. A comparison of adverse events and quality of life before and after switching from Kaletra™ Soft-gel to Kaletra™ Tablets in an African American cohort. 2007 American Conference for the Treatment of HIV (ACTHIV), Dallas, Texas, May 31-June 3, 2007. (Poster #82).

Williams JW, Golden W, Keck PE, Jewel M, Brewster C. Performance indicators for bipolar disorder: development and feasibility testing. 30th Annual Meeting of the Society of General Internal Medicine (SGIM), Toronto, Canada, April 2007.

Yeh, RF, Letendre S, Novak IS, et al. Single agent therapy with lopinavir/ritonavir controls HIV-1 replication in the central nervous system. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California, February 2007. (Poster 381).

Gathe Jr. JC, Lipman BA, Mayberry C, Miguel B, Nemecek J. Tolerability and therapy preference of lopinavir/ritonavir (Kaletra) Soft-gel capsules and tablets as single agent in a cohort of HIV positive adult patients (IMANI-2). Eighth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 2006. (Poster # P62).

Watson JT. Jones RC. Siston AM. Fernandez JR. Martin K. Beck E. Sokalski S. Jensen BJ. Arduino MJ. Srinivasan A. Gerber SI. Outbreak of catheter-associated Klebsiella oxytoca and Enterobacter cloacae bloodstream infections in an oncology chemotherapy center. Archives of Internal Medicine. 2005;165(22):2639-2643.

Shillington AC, Farley PA, Varkey JA, Dempsey C, Murdakes C. Retrospective cohort study of granisetron administration for PONV prophylaxis and treatment. Hospital Pharmacy. July 2005;40(7):592-598.

Caprini JA, Tapson VF, Hyers TM, et al. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. Journal of Vascular Surgery. 2005;42(4):726-733.

Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Archives of Internal Medicine. July 2005;165:1458-1464.
(click here to view Dr. Tapson interview by heartwire)

Waldo AL, Becker RC, Tapson VF, Colgan KJ. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. Journal of the American College of Cardiology. 2005;46(9):1729-1736.

Sharif A, Ajlouni M, Wollner I, et al. Oral capecitabine plus radiation therapy administered neoadjuvantly in the management of rectal cancer. 86th Annual Meeting of the American Radium Society (ARS), Napa Valley, California, May 2004.

Caprini JA, Ballard DJ, Becker RC, et al. Disparities in antithrombotic management. American Heart Association 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington DC, May 2004.

Tapson VF, Hyers TM, Becker RC, Waldo AL, Colgan KJ, Shillington AC. The National Anticoagulation Benchmark and Outcomes Report (NABOR™): evidence of a significant difference between guidelines and actual practice. International Society for Pharmacoeconomics and Outcomes Research 9th Annual International Meeting, Arlington, Virginia, May 2004.

Dempsey CL, Coop AJ, Shillington AC, Farley PA, Eberhardt DR, O’Briant S. Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. American Journal of Health-System Pharmacy. 2004;61(8):781-786.

Caprini JA, Marchev D, Glase C, et al. Venous thromboembolism treatment: results of a national database. American Venous Forum, Orlando, Florida, February 2004.

Jensen DM, Cotler SJ, Lam H, Harb G, Shillington AC. A comparison of hepatitis C treatment and outcomes at academic, private and Veterans’ Affairs treatment centers. Journal of Alimentary Pharmacology and Therapeutics. 2004;19(1):69-77(9).

Porter JA, Raebel MA, Conner DA, et al. The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) Study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care. 2004;10:369-376.

Billeter M, Levato J, Waldrep T, Dempsey CL, Farley PA. A multicenter drug utilization evaluation program for Timentin^®. ASHP Midyear Meeting, New Orleans, Louisiana, December 2003. (P-644E).

Shillington A, Dempsey C, Farley PA, Coop A, Eberhardt DR, Varkey JA. A descriptive practice evaluation of granisetron utilization in the management of postoperative nausea and vomiting. New York State Society of Anesthesia Annual Meeting, New York City, New York, December 2003.

Mortimer JE, Lauman MK, Tan B, Dempsey CL, Shillington AC, Hutchins KS. Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine. Journal of Oncology Pharmacy Practice. 2003;9(4):159-164.

Hindenburg AA, Matthews L. Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. a case report. International Journal of Gynecological Cancer. 2003;13(6):898-900.

Rich S, Shillington AC, McLaughlin V. Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. American Journal of Cardiology. 2003;92(11):1366-1368.

Rogers LR, Remer SE, Sheela Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy: case report. Neuro-oncology. 2004;6(1):63-64.

Coop AJ, Farley PA, Shillington AC, Dempsey CL, Colgan KC. 5-HT3 antiemetic use in breast cancer patients receiving cyclophosphamide: a multi-center practice evaluation. MASCC/ISOO 15th International Symposium, Berlin, Germany, June 2003. (Poster 7).

El-Rayes, BF ,Black CA, Ensley JF. Hormone-refractory prostate cancer responding to capecitabine. Urology. 2003;61(2):462xii-462xiv.

Hampton N, Romie A, Clewell L, Hadzima S, Gerdes JM. Management of community-acquired pneumonia in one hospital compared with a national benchmark database. Hospital Pharmacy. 2003;38(4):351-356.

back to top

2001 - 2002
Duckworth W, Marcelli M, Roman F, et al. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea co-administered with metformin to glyburide/metformin tablets. Academy of Managed Care Pharmacy, Washington, DC, October 2002. (Poster PDR 13).

Tan M, Xu R, Seth R. Granisetron vs. dolasetron for acute nausea and vomiting in high and moderately-high emetogenic chemotherapy. MASCC/ISOO 14th International Symposium, Boston, Massachusetts, June 2002. (Poster 117).

Rich S, Shillington A, McLaughlin VV. Prognosis of patients with primary pulmonary hypertension induced by fenfluramine diet pills. American Thoracic Society, Atlanta, Georgia, May 2002. (Abstract 37, Poster B15).

Vaishampayan UN, Ben-Josef E, Philip PA, et al. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiation Oncology Biology Physics. 2002;53(3):675-679.

McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477.

Romie AR, Aquayo S, Eagye K, Shillington A, Dempsey C. An evaluation of CAP management in the VA Healthcare System. ASHP Midyear Meeting, New Orleans, Louisiana, December 2001.

Romie AM, Farley A, Teeters J, Jewell MA. Integrated system evaluation of CAP management. ASHP Midyear Meeting, New Orleans, Louisiana, December 2001. (Abstract P671-E).

Shillington AC, Dempsey CL, Colgan KJ, Farley PA, Jewell MA. Shifting low risk CAP to the outpatient setting: implications for treatment selection. ASHP Midyear Meeting, New Orleans, Louisiana, December 2001. (Abstract P682-E).

Weber M, Reno S, Hornbake R, Shillington A. An in-home Synagis program for RSV prevention in high-risk infants. Journal of Managed Care Pharmacy. November/December 2001;7(6):476-481.

Jensen DM, Cotler SJ, Herb G, et al. Comparison of outcomes, treatment selection and completion in hepatitis C patients in academic and community based ambulatory treatment centers. AASLD Annual Meeting, Dallas, Texas, November 2001. (Abstract 404049).

Sokalski S, Jewell MA, Dempsey C, Shillington A. Evaluation of use and outcomes of IDSA Guidelines in patients with community-acquired pneumonia at low mortality risk. Infectious Diseases Society of America, San Francisco, California, October 2001.

Lonfield V, Hasan E, Romie A. A retrospective evaluation of the use of pyridoxine in the prevention and treatment of palmer-plantar erythrodysesthesia in capecitabine treated cancer patients Oncology Nursing Society, August 2001. (Abstract 11).

Romie AM, Dempsey CL, Shillington AC, Jewell MA, Farley PA. Effectively treating pneumonia as an outpatient: implications for the managed care pharmacist. AMCP Annual Meeting, Philadelphia, PA, April 2001.

Shillington AC, Hilley H, Carter WA, Strayer DR. Chronic fatigue syndrome (CFS): pharmacoeconomic analysis of Ampligen^® intervention. AACSF Annual Meeting, Seattle, Washington, February 2001.

1999 - 2000
Hampton N, Hadzima S, Clewell L. Romie AM, Gerdes J. Successful multidisciplinary implementation with electronic evaluation of community-acquired pneumonia. ASHP Midyear Meeting, Las Vegas, Nevada, December 2000. (Abstract P-285E).

Romie AM, Colgan K, Berstein G, Seshadri V, Dempsey CL. National severity-adjusted benchmark outcomes program for community acquired pneumonia. ASHP Midyear Meeting, Las Vegas, Nevada, December 2000. (Abstract P-282E).

Colgan K, Moody ML, Witte K. Responsible use of blood products in response to supply and demand. Am J Health-Syst Pharm. 2000;57:2094-2098.

Shillington AC. Ongoing issues in pneumonia care: when to admit, how to treat and the role of oral therapy. Journal of Medical Systems. 2000;24(5):297-306 (10).

Mizell PL, Harris S. Moore LA, et al. Successful implementation of a pneumonia outcomes management program in a large southeastern medical center. ASHP Annual Meeting, Philadelphia, Pennsylvania, June 2000. (Abstract P-47E).

Seshadri V, Dempsey CL, Romie AM, Shillington A. Clarithromycin vs. routine treatment in intervenous to oral switch for community-acquired pneumonia: an evaluation in 41 United States hospitals. ASHP Annual Meeting, Philadelphia, Pennsylvania, June 2000. (Abstract P-42D)

Carro G, Khandekar J, Seshadri V, Farley PA, Dempsey CL, Goliak MK. Prospective implementation of evidence based outcome management for chemotherapy induced nausea and vomiting in an outpatient setting. ASHP Midyear Meeting, Orlando, Florida, December 1999. (Abstract P-103D).

Moyers P, Ross J, Goliak MK, Seshadri V, Shillington A. Successful intervenous-to-oral switch outcomes in the management of pneumonia in an integrated system. ASHP Midyear Meeting, Orlando, Florida, December 1999. (Abstract 34:P-121E).

DeVoe MG, Broun ER, Sargent WK, Dempsey CL, Seshadri V. Clinical outcomes associated with the use of oral granisetron in bone marrow transplantation. ASHP Midyear Meeting, Orlando, Florida, December 1999. (Abstract P-462E).

Sokalski SJ, Shillington AC, Goliak M, et al. Benchmark evaluation of severity-adjusted outcomes and treatment associated with community acquired pneumonia. Infectious Disease Society of America, Philadelphia, Pennsylvania, November 1999.

Dempsey CL, Shillington AC, Jewell MA, Farley PA, Goliak MK. Optimizing management of hospitalized patients with community-acquired pneumonia. Infections in Medicine. 1999;16(10):670-684. (Continuing Education Credit).

Carro G, Rough S, Dempsey CL, Shillington AC, Khandekar JD. Clinical strategies for oral 5-HT3 receptor antagonist therapy for the prevention of chemotherapy-induced nausea and vomiting. Pharmacy and Therapeutics. 1999;24(10):494-506. (Continuing Education Credit).

Dempsey CL, Nicolau DP, Sokalski SJ, Shillington AC, Jewell MA, Goliak MK. Nursing home-acquired pneumonia: benchmarking treatment and outcomes in ten hospitals in the United States. Pharmacy & Therapeutics. 1999;24(8):390-398. (Continuing Education Credit).

Jewell MA, Dzelme A, Goliak MK, Dempsey CL. Determining cost effective treatment for pneumonia using the CAPPM software program for antibiotic selection. American Society of Heath Systems Pharmacists Annul Meeting, Reno, Nevada, June 1999. (CS-3).

Mullner RM, Jewell MA, Mease MA. Monitoring changes in home health care: a comparison of two national surveys. Journal of Medical Systems. 1999; 23(1):21-26.

back to top

1997 - 1998
Ramirez J, Kemmerly S, Simonson D, Mandler HD, Shillington AC. Cost effective care for pneumonia: using the ACES software program for intravenous to oral switch. ASHP Midyear Clinical Meeting, Las Vegas, Nevada, December 1998. (Abstract P-445E).

Bhat G, Jordan Jr. J, Sokalski S, Bajaj V, Marshall R, Berkelhammer, C. Minocycline-induced hepatitis with autoimmune features and neutropenia. Journal of Clinical Gastroenterology. 1998;27(1):74-75.

Dempsey CL, Shillington AC, Goliak M. Oral 5-HT3 receptor antagonists: expanding options for medicare outpatients. Journal of the American Pharmaceutical Association. 1998;38(5):515-516.

Clark CD, Abel SR, Dempsey CL, Shillington AC, Byun MH. Cost analysis of ondansetron and granisetron in the management of chemotherapy induced nausea and vomiting. Hospital Pharmacy. 1998;33:198-204.

Dempsey CL, Shillington AC, Jewell MA, Farley PA. Evaluation of nursing home acquired pneumonia treatment in the emergency departments of ten hospitals. ASHP Midyear Clinical Meeting, Atlanta, Georgia, December 1997. (Abstract P-385E).

Harris EM, Shillington AC, Dempsey CL, Blackwell B, Farley PA. Benchmarking evaluation of 5-HT3-receptor antagonist use in emetogenic chemotherapy. Hospital Formulary. 1997;32:515-516, 519-522.

Carro G, Rough SS, Dempsey CL, Shillington AC. Cost effective care using oral 5-HT3 receptor antagonists for preventing chemotherapy induced nausea and vomiting. ASHP Annual Meeting, Minneapolis, Minnesota, June 1997. (Abstract P-43E).

Rough SS, Carro G, Dempsey CL, Shillington AC. Developing and implementing oral 5HT3 receptor antagonist guidelines through a multidisciplinary process. ASHP Annual Meeting, Minneapolis, Minnesota, June 1997. (MCS-8).

Dempsey CL, Farley PA, Shillington AC, Cheff CM. Self reported assessment of functional status following 5-hydroxytryptamine 3 receptor antagonist therapy to chemotherapy induced nausea and vomiting in six cancer center. Association for Pharmacoeconomics and Outcomes Research, Philadelphia, Pennsylvania, April 1997. (Abstract# LC16).

Farley PA, Dempsey CL, Shillington AC, Kulis-Robitaille C, Colgan KJ, Bernstein G. Patients' self reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. American Journal of Health Systems Pharmacy. 1997;54:2478-2482.

back to top

1995 - 1996
Dempsey CL, Sokalski, SJ, Shillington, AS, Jewell, MA. A disease management study to improve outcomes associated with pneumonia. The Society for Medical Decision Making Annual Meeting, Toronto, Canada, October 1996.

Sokalski SJ, Shillington AS, Jewell MA, Dempsey CL. A multi-center benchmarking study to improve outcomes with pneumonia. The Infectious Disease Society of American Annual Meeting, New Orleans, Louisiana. September 1996.

Dempsey CL, Shillington AC, Farley PA, Gelone S, Nicolau D, Robitaille CK. Disease state management: development of a severity model for pneumonia. ASHP Annual Meeting, San Diego, California, June 1996. (P-34R).

Shillington AC, Dempsey CL, Farley PA, White RE, Harris E, Blackwell B. Risk assessment model for chemotherapy induced nausea and vomiting: using outcomes management in designing prevention strategies. ASHP Annual Meeting, San Diego, California, June 1996. (P-70 R).

Dempsey CL, Lewis GS. Pharmacoeconomics: overview and applications. The Journal of Pharmacy Practice. 1995;8:303-307.

Dempsey CL, Nicolau DP, Wagley W, Shillington AC, Jewell MA, Farley PA. Disease state management model for pneumonia: a multi-center benchmark project. Internal Medicine Physicians, Chicago, Illinois, June and October 1995. ASHP Midyear Clinical Meeting, December 1995. (P-281E).

Bernstein G, Colgan K, Martz C, et al. Quality of life assessment of patients receiving granisetron and ondansetron prior to and after chemotherapy. ASHP Midyear Clinical Meeting, December 1995. (P-46B).

Blackwell BG, Harris EM, Clark CD, et al. Disease state management model for chemotherapy induced nausea and vomiting: multi-center benchmark project. ASHP Midyear Clinical Meeting, December 1995. (P-195R).

Dempsey CL. Nursing home-acquired pneumonia: outcomes from a clinical process improvement program. Pharmacotherapy. 1995;15(1 Pt 2):33S-38S.

Jewell MA. Quantitative methods for quality improvement. Pharmacotherapy. 1995;15(1 Pt 2):27S-32S.

back to top

1994 and Prior
Dempsey CL. New pharmaceutical agents: a therapeutic summary. Pharmacy Times. 1994;60(April Suppl):7-14.

Dempsey CL, Kaley TC, Zendel J. Drug usage evaluation: clarithromycin as sequential therapy. Hospital Formulary. 1993;28:999-1001.

Sokalski SJ, Jewell MA, Asmus-Shillington AC, Mulcahy J, Segreti J. An outbreak of serratia marcescens in 14 adult cardiac surgical patients associated with 12-lead electrocardiogram bulbs. Archives of Internal Medicine. 1992;152(4):841-844.

Fliegelman RM, Mattingly PM, Dempsey CL, Solkalski SJ. Economic impact of oral ciprofloxacin following standard intravenous therapy. Diag Microbiol Infect Dis. 1990;13:187-189.

Fligner DJ, Wigder HN, Harter PM, Fliegelman RM, Jewell M, Perlman P. The prevalence of hepatitis B serological markers in suburban paramedics. The Journal of Emergency Medicine. 1989;7(1):41-45.

back to top